Gerald Raverot
Gerald Raverot is an expert in Endocrinology at Hospices Civils de Lyon (France). As of October 2026, ScienceLeadR ranks Gerald Raverot in the top 1% of experts worldwide for Pituitary Neoplasms, Hypothalamic Diseases and Pituitary Diseases. Gerald Raverot has authored 398 publications, the most recent in 2026, and is an investigator in 14 clinical trials, 3 of them ongoing. SLR score: 1,308 (community average: 125). How the SLR is computed.
LeadR Profile
Endocrinology
Subspecialties: Oncology - Neurology - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Short Biography
Organizations
Career arc: 2011 - 2026
Number : 398
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Genetic testing and reporting: What the endocrinologists should know and can expect (Joint position paper of the ENDO-ERN). PMID 42744303 — research design, high-throughput nucleotide sequencing, genetic testing, laboratories, workflow, endocrinologists, hormones | Eur J Endocrinol | 2026 | 0 |
| Impact of pituitary adenoma histological subtype on remission and disease control in acromegaly. PMID 42046892 — endocrinology, growth hormone-secreting pituitary adenoma, prolactin, acromegaly, adenoma | J Clin Endocrinol Metab | 2026 | 0 |
| GHRH and insulin hypersecretion from a pancreatic neuroendocrine tumor in multiple endocrine neoplasia type 1. PMID 42007244 — insulin, multiple endocrine neoplasia type 1, neoplasms, multiple endocrine neoplasia, insulinoma, hormones, acromegaly, neuroendocrine tumors, neuroectodermal tumors, primitive, hypoglycemia | JCEM Case Rep | 2026 | 0 |
| Therapy for aggressive pituitary tumors and carcinomas. PMID 41995969 — neoplasms, therapeutics, pituitary neoplasms | Rev Endocr Metab Disord | 2026 | 0 |
| Genomic characterization of aggressiveness in pituitary neuroendocrine tumors (PitNETs). PMID 41955313 — brain neoplasms, genes, transcriptome, neoplasms, neuroendocrine tumors | Neuro Oncol | 2026 | 0 |
Clinical Studies 14
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A randomized placebo controlled trial to evaluate the safety and efficacy of Debio 4126 in patients with acromegaly previously treated with somatostatin analogs 2024-516616-24-00 — somatostatin, safety, acromegaly, octreotide | Phase 3 | Recruiting | 2025 |
| How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin secreting Tumors NCT07268183 — cells, telephone, estrogens, hormonal contraception, prolactinoma, neoplasms, contraception, lactotrophs, reproductive history, amenorrhea, signs and symptoms, prolactin, sex, risk factors, diagnosis, adenoma, galactorrhea, therapeutics, menopause, history, contraceptive agents, pituitary neoplasms, male, men, women | N/A | Recruiting | 2026 |
| A Research Registry on Aggressive PitNETs NCT05974696 — registries, rare diseases, neoplasms, endocrine gland neoplasms, endocrine glands, work, research | N/A | Recruiting | 2023 |
LeadR Networks
Main global connection map